Aficamten Clinical Trials (2026): 7 Studies for Obstructive Hypertrophic Cardiomyopathy (oHCM) & Obstructive Hypertrophic Cardiomyopathy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 Aficamten clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Obstructive Hypertrophic Cardiomyopathy (oHCM) & Obstructive Hypertrophic Cardiomyopathy) and 2,006 total planned enrollment. 4 Phase 3 Aficamten trials are listed. 1 Aficamten clinical trial is actively recruiting. Most recent activity: NCT06412666 (Jan 2030).
Aficamten clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | enrolling by invitation | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2/P3 | 1 | 1 | 2 | |
| P3 | 1 | 3 | 4 |
Recruiting Aficamten clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04848506 | FOREST-HCMOpen-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | P2/P3 | Symptomatic Hypertrophic Cardiomyopathy (HCM) | 900 | May 2021 |
Aficamten clinical trials by indication
Obstructive Hypertrophic Cardiomyopathy (oHCM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05767346 | MAPLE-HCM | P3 | completed | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM |
| NCT05186818 | SEQUOIA-HCM | P3 | completed | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM |
Pediatric (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06412666 | CEDAR-HCM | P2/P3 | active not recruiting | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). |
Obstructive Hypertrophic Cardiomyopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06116968 | — | P3 | completed | An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM |
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06081894 | ACACIA-HCM | P3 | active not recruiting | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05924815 | — | P1 | completed | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval |
Symptomatic Hypertrophic Cardiomyopathy (HCM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04848506 | FOREST-HCM | P2/P3 | enrolling by invitation | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM |
Aficamten pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ACACIA-HCM | NCT06081894 | P3 | active not recruiting | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | 500 | — |
| MAPLE-HCM | NCT05767346 | P3 | completed | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 175 | — |
| SEQUOIA-HCM | NCT05186818 | P3 | completed | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 282 | — |
All Aficamten trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06412666 | CEDAR-HCM | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | P2/P3 | active not recruiting | 65 | Cytokinetics | May 2024 |
| NCT04848506 | FOREST-HCM | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | P2/P3 | enrolling by invitation | 900 | Cytokinetics | May 2021 |
| NCT06081894 | ACACIA-HCM | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | P3 | active not recruiting | 500 | Cytokinetics | Aug 2023 |
| NCT06116968 | An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM | P3 | completed | 40 | Corxel Pharmaceuticals | Nov 2023 | |
| NCT05767346 | MAPLE-HCM | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM | P3 | completed | 175 | Cytokinetics | Jun 2023 |
| NCT05186818 | SEQUOIA-HCM | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM | P3 | completed | 282 | Cytokinetics | Feb 2022 |
| NCT05924815 | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | P1 | completed | 44 | Cytokinetics | May 2023 |
Aficamten clinical trials: frequently asked questions
- How many Aficamten clinical trials are there?
- 7 Aficamten clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 4 are marked completed.
- Are Aficamten clinical trials recruiting in 2026?
- Yes — 1 Aficamten trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Aficamten being studied for?
- Aficamten is being studied for Obstructive Hypertrophic Cardiomyopathy (oHCM), Obstructive Hypertrophic Cardiomyopathy, Healthy Participants, Symptomatic Hypertrophic Cardiomyopathy (HCM), Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy and 2 more. The trials are grouped by indication on this page.
- What phase is Aficamten in?
- Aficamten clinical trials span 4 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Aficamten clinical trials?
- The lead sponsor across the most Aficamten trials is Cytokinetics, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Aficamtenas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: